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The interplay between genotype, metabolic state and cofactor
treatment governs phenylalanine hydroxylase function and drug
response
Abstract
The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions about
function and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient in this disease. To
investigate the interdependence of the genotype, the metabolic state (phenylalanine substrate) and
treatment (BH(4) cofactor) in the context of enzyme function in vitro and in vivo, we (i) used a
fluorescence-based method for fast enzyme kinetic analyses at an expanded range of phenylalanine and
BH(4) concentrations, (ii) depicted PAH function as activity landscapes, (iii) retraced the analyses in
eukaryotic cells, and (iv) translated this into the human system by analyzing the outcome of oral BH(4)
loading tests. PAH activity landscapes uncovered the optimal working range of recombinant wild-type
PAH and provided new insights into PAH kinetics. They demonstrated how mutations might alter
enzyme function in the space of varying substrate and cofactor concentrations. Experiments in
eukaryotic cells revealed that the availability of the active PAH enzyme depends on the
phenylalanine-to-BH(4) ratio. Finally, evaluation of data from BH(4) loading tests indicated that the
patient's genotype influences the impact of the metabolic state on drug response. The results allowed for
visualization and a better understanding of PAH function in the physiological and pathological state as
well as in the therapeutic context of cofactor treatment. Moreover, our data underscore the need for
more personalized procedures to safely identify and treat patients with BH(4)-responsive PAH
deficiency.
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The discovery of a pharmacological treatment for phenylketonuria (PKU) raised new questions about func-
tion and dysfunction of phenylalanine hydroxylase (PAH), the enzyme deficient in this disease. To investigate
the interdependence of the genotype, the metabolic state (phenylalanine substrate) and treatment (BH4 cofac-
tor) in the context of enzyme function in vitro and in vivo, we (i) used a fluorescence-based method for fast
enzyme kinetic analyses at an expanded range of phenylalanine and BH4 concentrations, (ii) depicted PAH
function as activity landscapes, (iii) retraced the analyses in eukaryotic cells, and (iv) translated this into
the human system by analyzing the outcome of oral BH4 loading tests. PAH activity landscapes uncovered
the optimal working range of recombinant wild-type PAH and provided new insights into PAH kinetics.
They demonstrated how mutations might alter enzyme function in the space of varying substrate and cofac-
tor concentrations. Experiments in eukaryotic cells revealed that the availability of the active PAH enzyme
depends on the phenylalanine-to-BH4 ratio. Finally, evaluation of data from BH4 loading tests indicated
that the patient’s genotype influences the impact of the metabolic state on drug response. The results
allowed for visualization and a better understanding of PAH function in the physiological and pathological
state as well as in the therapeutic context of cofactor treatment. Moreover, our data underscore the need
for more personalized procedures to safely identify and treat patients with BH4-responsive PAH deficiency.
INTRODUCTION
Phenylketonuria (PKU; OMIM #261600), the most common
inborn error of amino acidmetabolism, is an autosomal recessive
disorder caused by phenylalanine hydroxylase (PAH) deficiency
(PAH; EC 1.14.16.1) (1). Currently, 627 different disease-
causing mutations in the PAH gene are known (www.pahdb.m
cgill.ca; www.hgmd.org) and some of these were shown to
lead to protein misfolding with loss of function (2–4).
Pharmacological doses of 6R-L-erythro-5,6,7,8-tetrahydro-
biopterin (BH4), the enzyme’s natural cofactor, can reduce
blood phenylalanine concentrations (5–10) and increase
phenylalanine oxidation rates in vivo (11) in patients with
PAH deficiency without any evidence of cofactor deficiency.
The compound was shown to rescue the biochemical pheno-
type by correcting PAH misfolding and was thus classified
as a pharmacological chaperone (4,12). Following these
studies, sapropterin dihydrochloride, the synthetic form of
the natural PAH cofactor, was approved as an orphan drug
to alleviate or even replace burdensome dietary treatment in
a significant share of patients with PKU due to PAH deficiency
(13–16).
However, not all patients show BH4 responsiveness. Since
the introduction of sapropterin dihydrochloride as a pharmaco-
logical treatment, many attempts to predict BH4 responsive-
ness from a patient’s genotype were made (17–19).
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Combined evidence seems to support the view that residual
enzyme activity of individual mutations may be a parameter
that—to some extent—allows for discrimination of responders
and non-responders (19–22). In two studies performed on
Croatian and Turkish populations, calculation of mean in
vitro residual enzyme activity of the two PAH variants
arising from both alleles led to the identification of some
responders with high accuracy, whereas patients with two
fully inactive alleles were found to be always non-responders
(19,22). Yet, in many instances, no clear genotype–phenotype
correlation is found pointing to contributing factors such as the
patient’s age or initial blood phenylalanine concentrations
(17,19). Marked inconsistencies as to BH4 responsiveness
were observed for two of the most common PKU mutations
associated with this particular phenotype, R261Q and
Y414C (17) and for R252W, L48S and R241C homozygous
genotypes (22). In addition, interpretation of genotype
effects is hampered by the fact that .80% of BH4 responders
are compound heterozygous (17).
Hydroxylation of the substrate L-phenylalanine to the
product L-tyrosine with the use of the natural cofactor BH4
and molecular oxygen is a complexly regulated catalytic
mechanism. While L-phenylalanine induces activating confor-
mational rearrangements, BH4 leads to the formation of an
inactive dead-end PAH–BH4 complex (23–26). Recent
studies unraveled new aspects concerning the interplay of
phenylalanine and BH4 having an impact on enzyme kinetics
as well as on drug response. Adoption of an enzyme activity
assay using a newly developed fluorescence-based real-time
PAH activity assay revealed cooperativity of recombinant
PAH towards the BH4 cofactor. This was restricted to the
phenylalanine substrate-activated state of the enzyme indicat-
ing that conformational rearrangements of the PAH protein
induce cooperative binding (27). Moreover, investigations of
the BH4 effect in two different mouse models for BH4-
responsive PAH deficiency provided evidence that the
response to BH4 in terms of rescue of enzyme function by
increasing the effective intracellular PAH amount also
depends on phenylalanine concentrations and on the under-
lying genotype (12). These results suggested that the influence
of substrate and cofactor concentrations in the presence of a
certain genotype on enzyme function and on the response to
the pharmacological chaperone BH4 might be of even more
functional and therapeutic relevance than previously esti-
mated. In addition, the BH4 loading test routinely used world-
wide to assess BH4 responsiveness in PAH deficiency (28,29)
was shown to result in a number of inconsistencies that are
still not well understood. In some but not all cases, this may
be due to inadequate BH4 dosage or to initial blood phenyl-
alanine concentrations near to the physiological state. Unfortu-
nately, this may lead to false negative results precluding
cofactor treatment and thus increasing burden of treatment
in some BH4-responsive patients.
To address these issues, (i) we adapted our new
fluorescence-based method for fast enzyme kinetic analyses
to cover an expanded range of phenylalanine and BH4 concen-
trations when compared with previous analytical setups
enabling the investigation of the mutual impact of substrate
and cofactor on PAH enzyme kinetics, (ii) we depicted these
data as activity landscapes uncovering the optimal working
range of recombinant wild-type and mutated PAH, (iii) we
retraced these analyses in a eukaryotic cell culture system,
revealing that the availability of the active PAH enzyme
depends on both the metabolic state and drug dosage, and
(iv) we translated this into the human system by analyzing
the effect of the genotype, phenylalanine concentrations and
the BH4 dosage applied on the results of oral BH4 loading
tests from PAH-deficient patients.
RESULTS
Expanded insights into wild-type PAH kinetics unraveling
the mutual impact of substrate and cofactor concentrations
In order to investigate the interdependence of L-phenylalanine
and BH4 in PAH enzyme kinetics, we adapted a newly devel-
oped fluorescence-based real-time activity assay (27) to simul-
taneously analyze the effect of a wide range of substrate and
cofactor concentrations on PAH activity. Process automation
now allowed for continuous measurement of tyrosine
product formation over time in one single operation consisting
of six sequential runs for all 96 wells (Fig. 1A). The assay was
expanded to cover the space of 0 to 4000 mM L-phenylalanine
and 0–500 mM BH4 (Fig. 1B). First, we validated the data
obtained with the new method by comparison with previous
findings using a standard high-performance liquid chromato-
graphy (HPLC) based discontinuous assay (2). Data points
determined at either varying L-phenylalanine concentrations
(0–1000 mM) and one BH4 concentration (75 mM) or at one
L-phenylalanine concentration (1000 mM) and varying BH4
concentrations (0–125 mM), respectively, were used to calcu-
late enzyme kinetic parameters. Prior to calculation, an F-test
was used to decide whether the Michaelis–Menten or the Hill
kinetic model was more appropriate (27). Both L-phenylalanine
and BH4-dependent PAH enzyme kinetics showed clear data-
fitting to the Hill equation (Fig. 1C), as previously described
for the L-phenylalanine-activated enzyme (27). Although
Vmax values for L-phenylalanine and BH4-dependent kinetics
were higher in the new assay, allosteric parameters, i.e. appar-
ent substrate affinity, the Hill coefficient and apparent cofactor
affinity, were similar in both assays (Table 1).
We depicted the data analyzed by non-linear and poly-
nomial regression fitting as three-dimensional landscapes of
enzyme activity (30). This enabled a visual representation of
the mutual impact of substrate (x-axis) and cofactor concen-
trations (y-axis) on PAH kinetics (color code) representing
functional conditions of the PAH enzyme. Wild-type PAH
showed a peak maximum enzyme activity at 575 mM
L-phenylalanine and 125 mM BH4, respectively (Fig. 1D).
The analysis of PAH enzyme kinetics at BH4 and
L-phenylalanine concentrations extended to supraphysiological
levels led to a number of interesting observations. High PAH
enzyme activity was determined at a surprisingly wide range
of substrate and cofactor concentrations. The optimal
working range reflected by PAH enzyme activity in the bound-
aries of [S]0.5 to Ki for the substrate and [C]0.5 to Ki for the
cofactor spanned from 252 to 2026 mM L-phenylalanine and
from 44 to 306 mM BH4 (Table 2). At L-phenylalanine concen-
trations above 561 mM, we observed the well-known substrate
inhibition of enzyme activity (30,31). Notably, at cofactor
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concentrations above 108 mM cofactor inhibition occurred. In
addition, a mutual interdependence of both inhibitory events
was found. These observations represent previously
unknown findings. Over and above that, at L-phenylalanine
concentrations within the range naturally occurring in the
pathological state (500–1500 mM), the enzyme requires more
BH4 with increasing L-phenylalanine concentrations to main-
tain the same level of enzyme activity.
Taken together, the considerable extension of analysis con-
ditions and the evaluation of data by compiling activity land-
scapes provided new insights into PAH kinetics. It allowed for
a precise evaluation of peak PAH enzyme activity and the
Figure 1. Optimal working range of wild-type PAH activity. (A) Scheme of sequential measurements of PAH enzyme kinetics in a 96-well plate. One sequence
consists of two columns (red box). In each column, cofactor concentrations (0–500 mM) were varied at a fixed substrate concentration (0–4000 mM), respectively.
Repeated cycles allowed for kinetic measurements of 16 wells over a time period of 90 s. (B) Extension of substrate and cofactor concentrations. The range of
L-phenylalanine and BH4 concentrations was expanded from standard conditions (BH4, 75 mM; L-phenylalanine 1000 mM, red box) to 500 mM BH4 and 4000 mM
L-phenylalanine (arrows), respectively. (C) Cooperativity of PAH towards substrate and cofactor. Pre-activated PAH showed sigmoidal behavior for
L-phenylalanine- (upper panel) and BH4-dependent (lower panel) PAH enzyme kinetics. (D) Activity landscape of human wild-type PAH. Data for PAH
enzyme activity assayed at varying L-phenylalanine and BH4 concentrations were interpolated and depicted by a color code. The dot-and-dash line represents
Ki for substrate inhibition at varying cofactor concentrations, the dotted line represents Ki for cofactor inhibition at varying substrate concentrations. With
increasing substrate concentrations, more BH4 is needed to maintain the same level of enzyme activity (solid line).
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optimal working range spanning a wide area of substrate and
cofactor concentrations. Moreover, cofactor inhibition as
well as a mutual impact of substrate and cofactor concen-
trations on PAH activity have been identified.
Activity landscapes: the effect of PAH mutations on PAH
enzyme kinetics
Variant PAH proteins harboring mutations mapping to the
regulatory (F39L, I65T), the catalytic (R216Q, P275L,
P314S, V388M) and the dimerization motif of the oligomeri-
zation domain (Y414C, Y417H) of the enzyme were analyzed.
The results from kinetic measurements were depicted as
activity landscapes and compared with those from wild-type
PAH (Fig. 2). For each variant analyzed, enzyme kinetic par-
ameters and peak enzyme activities with their corresponding
L-phenylalanine or BH4 concentrations were determined
(Tables 2 and 3). The area of optimal enzyme activity
defined as the range [S]0.5 to Ki for the substrate and [C]0.5
to Ki for the cofactor, respectively, was calculated (Table 2).
The variant proteins bearing the mutation F39L or I65T,
both located in the regulatory domain, showed at first glance
a landscape pattern comparable with that of the wild-type.
Besides enzyme activity (F39L, 92%; I65T, 55%), the variants
displayed unaffected enzyme kinetic parameters as well as
similar effects of substrate and cofactor inhibition as found
for the wild-type enzyme. However, a more detailed analysis
revealed that peak PAH activities were found at similar sub-
strate concentrations, but at 1.3-fold higher cofactor concen-
trations when compared with the wild-type. This indicates that
in the presence of these mutations, more cofactor is needed to
achieve optimal PAH function.
All mutations mapping to the catalytic domain induced
marked alterations of activity landscapes. For the variant
R261Q, the area of substantial PAH activity was much
larger than for the wild-type, but residual enzyme activity
was reduced to 42%. The concentrations of substrate and
cofactor needed to achieve peak PAH activity were shifted
to higher values (L-phenylalanine, 1.5-fold; BH4, 1.4-fold).
We observed reduced affinity to the substrate by a factor of
0.5 ([S]0.5 282 mM). Binding of BH4 followed Michaelis–
Menten kinetics representing a loss of cooperativity that
occurred with reduced affinity (Km 66 mM). Broadening of
the landscape resulted from a significant shift of enzyme inhi-
bition. Notably, the variant did not display cooperative binding
of BH4 when activated. Taken together, the unique feature of
Table 2. Peak enzyme activity and range of substrate and cofactor concentrations of wild-type and variant PAH
Peak activity L-phenylalanine BH4
(nmol L-tyrosine/min
× mg protein)
Residual
activity (%)
concentration at
peak activity (mM)
[S]0.5–Ki
§ concentration at
peak activity (mM)
[C]0.5–Ki or Km–Ki
§
WT 6370 100 561 252–2026 108 44–306
F39L 5865 92 622 187–2275 143 35–331
I65T 3533 55 612 254–2075 135 29–322
R261Q 2654 42 842 344–2825 149 41–321
P275L 5215 82 1293 238–1980 334 71–435
P314S 1956 31 612 76–1043 80 42–218
V388M 6355 100 591 201–1933 105 47–296
Y414Ca 3106 49 591 124–1048a 105 43–274
Y417H 5206 82 471 147–1501 92 63–262
Peak enzyme activity of variant tetramericMBP–PAH fusion proteinsmeasured by direct in-well activitymeasurements. The apparent affinities for L-phenylalanine (S0.5)
and BH4 (C0.5/Km) as well as Ki for substrate and cofactor inhibition were calculated based on non-linear regression analysis at L-phenylalanine and BH4 concentrations
of peak enzyme activity.
§Ki calculated at peak L-phenylalanine and BH4 concentrations using the Boltzman-sigmoidal equation.
aCalculation of Ki at a range of L-phenylalanine 0–1624 mM.
Table 1. Comparison of enzyme kinetic parameters of human wild-type MBP–PAH at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min× mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min × mg protein) [C]0.5 (mM) Km (mM) hBH4
Continuous assay 5407+210 145+11 3.3 5222+286 23+2 2.0
Discontinuous assay 3470+75 155+6 3.0 3425+139 24+3
Steady-state kinetic parameters of wild-type MBP–PAH fusion proteins. Vmax and the apparent affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as
the Hill coefficient (h) as a measure of cooperativity are shown. Enzyme kinetic parameters were determined from enzyme activities measured using the newly
developed fluorescence-based continuous assay and compared with enzyme activities measured by the standard HPLC-based discontinuous assay (2). Data were
analyzed using the F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Values
are given as mean+SEM of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
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the R261Q variant was the right shift of PAH enzyme activity
towards higher L-phenylalanine concentrations indicating a
reduced affinity of this variant to its substrate and that the
enzyme displays low activity at L-phenylalanine concen-
trations below 600 mmol/l. At these substrate concentrations,
even very high BH4 doses would not produce any response
in PAH activity. The presence of the mutation P275L resulted
in an enzyme with overall high residual enzyme activity
(82%), yet with a shift of peak enzyme activity to 2.3-fold
higher L-phenylalanine and 3-fold higher BH4 concentrations
(L-phenylalanine 1293 mM, BH4 334 mM) than the wild-type.
In comparison to the wild-type, the enzyme had a substantially
higher need for BH4 to achieve the optimal working range. As
a consequence, substrate and cofactor inhibition was almost
abolished. The variant protein bearing the mutation P314S
showed a severe loss in residual enzyme activity (31%) with
Figure 2. Activity landscapes of recombinant wild-type and variant PAH. The interpolated specific enzyme activities are color-coded and given as a function of
different L-phenylalanine and BH4 concentrations. Substrate and cofactor inhibition are depicted as a summation line (black dotted line). Positions of S0.5 and Ki
for L-phenylalanine and C0.5 and Ki for BH4, respectively, are indicated at peak enzyme activities (open circles). Marked changes in the activity landscape of
variant PAH when compared with the wild-type (WT) are highlighted (open triangles) and BH4 concentrations needed to maintain the same enzyme activity with
increasing L-phenylalanine concentrations are shown (red dotted line).
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a narrow optimal working range that was shifted towards
lower L-phenylalanine as well as BH4 concentrations. In
addition, enzyme kinetics revealed a significantly increased
apparent affinity to the substrate with marked reduction in
cooperativity. In contrast to previous findings (3,32), where
the variant protein V388M was described as a Km variant
with reduced affinity to the cofactor, we detected high residual
enzyme activity over an expanded range of substrate and
cofactor concentrations. Residual PAH activity was 100%
and peak catalysis (L-phenylalanine 591 mM, BH4 105 mM) as
well as effects of substrate and cofactor inhibition were
similar to that of the wild-type enzyme.
Mutations mapping to the oligomerization domain, Y414C
and Y417H, showed a narrowed optimal working range that
was shifted to lower substrate concentrations. However, this
was less pronounced for the milder mutation Y417H (82%
residual enzyme activity) when compared with Y414C
(49%). On the other hand, Y417H needed less BH4 to
achieve the area of optimal function. Interestingly, different
to all variants analyzed, Y414C showed two peaks of high
enzyme activity.
Taken together, we identified many similarities between the
activity landscapes of the wild-type and variant PAH proteins,
showing generally high residual enzyme activity as well as
substrate and cofactor inhibition. However, these activity land-
scapes also revealed important differences in the regulation of
PAH activity by BH4 and L-phenylalanine and helped to visu-
alize the interdependence of substrate and cofactor concen-
trations on variant PAH enzyme activity.
Cofactor action on PAH function in respect of kinetic
behavior and the chaperone effect
We used two different approaches to analyze different aspects
of cofactor action on the wild-type, R261Q and Y414C PAH
enzyme in HEK293 cells. First, we in part retraced the activity
landscapes analyzing the kinetic behavior by assaying enzyme
activity of cell lysates at different L-phenylalanine
concentrations (0–1000 mM) while keeping the BH4 concen-
tration constant (75 mM) (Fig. 3A). Secondly, we analyzed
the chaperone effect of the BH4 cofactor at different phenyl-
alanine and BH4 concentrations after a 72 h incubation.
As expected, the wild-type protein showed the highest
enzyme activity of all three proteins analyzed with a peak
activity at about 250 mM L-phenylalanine. The latter finding
differed from the peak activity observed for recombinant
PAH at 500 mM. As seen for prokaryotic PAH, a further
increase in L-phenylalanine concentrations resulted in sub-
strate inhibition. The variant R261Q displayed 50% residual
enzyme activity and a lower slope of the curve that leveled off
at a plateau. Reduced enzyme function, which was shifted
toward higher substrate concentrations with a broadened
working range, substantiated results from activity landscapes.
Residual enzyme activity of eukaryotic Y414C was substan-
tially lower than the specific activity of the corresponding
recombinant variant. In addition to peak activity at 180 mM
L-phenylalanine, a second slight incline of activity was
observed at high L-phenylalanine concentrations (1000 mM).
Although generally shifted toward lower substrate concen-
trations, this is in line with the two peaks observed in the
activity landscape.
Next, we aimed to elucidate the long-term chaperone effect
of varying intracellular phenylalanine and BH4 concentrations
on PAH function. The determination of enzyme activity at stan-
dard conditions after previous incubation of cells with different
substrate and cofactor concentrations assays the availability of
functionally active PAH. For this purpose, stably transfected
cells were cultivated with L-phenylalanine concentrations of
91, 500 or 1200 mM and BH4 concentrations of 0, 40 or
75 mM for 72 h. First, cells were cultivated at L-phenylalanine
levels representing the physiological state (91 mM), mild PKU
(500 mM) or classical PKU (1200 mM) without the addition of
BH4 to the medium (Fig. 3B). Wild-type PAH activity
showed a trend towards an increase only at clearly pathological
L-phenylalanine concentrations. For R261Q, a steady but stat-
istically not significant increase in enzyme activity was seen
Table 3. Enzyme kinetic parameters at standard L-phenylalanine (1000 mM) and BH4 (75 mM) concentrations calculated from activity landscapes
L-phenylalaninea BH4
b
Vmax (nmol L-tyrosine/min × mg protein) [S]0.5 (mM) hPhe Vmax (nmol L-tyrosine/min × mg protein) [C]0.5 (mM) Km (mM) hBH4
WT 5407+210 145+11 3.3 5222+286 23+2 2.0
F39L 4961+342 115+15 2.7 5669+311 36+3 1.7
I65T 3166+96 161+10 2.7 3277+196 27+3 1.7
R261Q 3041+128 282+18 3.4 4693+598 66+17
P275L 3204+126 112+8 2.6 3022+179 36+3 2.8
P314S 1650+91 76+9 1.8 991+25 24+1 5.2
V388M 5639+112 140+6 2.7 5895+236 26+2 1.8
Y414C 2895+206 120+17 2.4 2148+203 28+4 2.6
Y417H 4434+247 111+10 3.6 3011+93 23+1 2.5
Steady-state kinetic parameters of variant tetrameric MBP–PAH fusion proteins determined by direct in-well activity measurements. Data were analyzed using the
F-test for model comparison and the kinetic parameters of the best-fitting model (cooperative versus non-cooperative) were calculated. Vmax and the apparent
affinities for L-phenylalanine (S0.5) and BH4 (C0.5, Km) as well as the Hill coefficient (h) as a measure of cooperativity are shown. Values are given as mean+SEM
of three independent measurements.
aEnzyme kinetic parameters determined at variable L-phenylalanine concentrations (0–1000 mM) and standard BH4 concentration (75 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
bEnzyme kinetic parameters determined at variable BH4 concentrations (0–125 mM) and standard L-phenylalanine concentration (1000 mM) with pre-incubation of
the enzyme by L-phenylalanine (1000 mM).
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upon increasing substrate concentrations in the medium (35+5
to 52+9 pmol L-tyrosine/min × mg total protein). For Y414C,
residual activity was very low without any effect of increasing
L-phenylalanine concentrations.
To further evaluate the mutual impact of the substrate and
the cofactor on enzyme activity in the eukaryotic system, 40
or 75 mM BH4 were added to the medium at L-phenylalanine
concentrations of 91 or 1200 mM, respectively (Fig. 3C).
Figure 3. Cofactor action on PAH function in respect of kinetic behavior and the chaperone effect. (A) Enzyme activity of eukaryotic expressed PAH assayed at
varying substrate concentrations. Enzyme activities in cell lysates of HEK293 cells stably transfected with wild-type PAH, R261Q or Y414C were determined at
varying L-phenylalanine concentrations (0–1000 mM) and a fixed BH4 concentration (75 mM). (B) Effect of varying intracellular phenylalanine concentrations on
functionally active PAH. PAH enzyme activity in HEK293 cell lysates expressing wild-type PAH, R261Q or Y414C was determined at standard assay concen-
trations (1000 mM L-phenylalanine and 75 mM BH4) after prior incubation with different L-phenylalanine concentrations (black, 91 mM; dark gray, 500 mM; white,
1200 mM) for 72 h. (C) Mutual impact of varying substrate and cofactor concentrations on functionally active PAH. Cells stably expressing wild-type PAH,
R261Q or Y414C were cultivated at different phenylalanine (left column, 91 mM; right column, 1200 mM) and BH4 concentrations (white, 0; dark gray,
40 mM; and black, 75 mM). PAH enzyme activities were analyzed at standard assay conditions. PAH activities are given as mean+SEM of three independent
experiments. Significant differences in enzyme activities were calculated using one-way ANOVA and Dunnett’s multiple comparison test (ns, not significant;
∗P , 0.05; ∗∗P , 0.01).
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Interestingly, at physiological L-phenylalanine concentrations
(91 mM), the addition of 40 and 75 mM BH4 induced a trend
towards increased enzyme activity of wild-type PAH (57+
9 to 98+ 22 and 105+ 18 pmol L-tyrosine/min × mg total
protein), whereas the opposite effect was observed at elevated
L-phenylalanine concentrations (1200 mM L-phenylalanine,
108+ 37 to 40+ 7 and 35+ 5 pmol L-tyrosine/min × mg
total protein). For the variant R261Q, the addition of 40 mM
BH4 at physiological L-phenylalanine concentrations resulted
in a significant increase in enzyme activity (35+ 5 to 86+
17 pmol L-tyrosine/min × mg total protein), but the inhibitory
effect at elevated L-phenylalanine concentrations as seen for
the wild-type was not observed. At physiological
L-phenylalanine concentrations, the variant Y414C showed
low residual enzyme activity with only a minor increase
upon the addition of 40 mM BH4. Interestingly, at high
L-phenylalanine concentrations (1200 mM), the addition of 40
but not 75 mM BH4 led to a significant increase in residual
enzyme activity (23+ 4 pmol L-tyrosine/min × mg total
protein) achieving as much as 40% of the wild-type level.
Taken together, findings from the prokaryotic system
depicted by activity landscapes were substantiated in the
eukaryotic environment. Also in this system probing lysates
of cultured cells, the mutual impact of different
L-phenylalanine and BH4 concentrations on enzyme activity
varied among different PAH variants with substrate inhibition
for the wild-type as well as constant activity levels for R261Q
also at very high L-phenylalanine concentrations. Residual
enzyme activity of Y414C was substantially lower in cell
culture when compared with the specific activity of the recom-
binant protein, but enzyme function was rescued by the
addition of BH4. This may point to impaired protein stability
in the eukaryotic environment and a stabilizing pharmacologi-
cal chaperone effect by BH4.
The mutual impact of substrate and cofactor
concentrations on results from BH4 loading tests
performed in PAH deficient patients
So far, data pointed to a simultaneous dependency of PAH func-
tion from available substrate and cofactor concentrations. After
having confirmed results from the prokaryotic system in the
eukaryotic system, we aimed to investigate whether our obser-
vations may be transferred to the human situation by analyzing
data from BH4-loading tests performed in patients with PAH
deficiency. To address this issue, we collected data of patients
homozygous or functionally hemizygous for the mutations
F39L, I65T, R261Q or Y414C, that underwent a BH4-loading
test with a dose of 20 mg/kg body weight and a duration of at
least 24 h from the literature (19,33–37) and from the
BIOPKU database (www.biopku.org). First, we compiled the
course of blood phenylalanine values within 24 h after a single
dose of BH4 as a function of initial blood phenylalanine concen-
trations. For all mutations analyzed, different blood phenyl-
alanine concentrations at the beginning of the test led to
differences in the extent of BH4 responsiveness, i.e. the
percent decrease in blood phenylalanine after drug adminis-
tration. Patients carrying the mutations F39L, I65T and
Y414C showed a peak level of BH4 responsiveness below an
initial blood phenylalanine concentration of 500 mM (Fig. 4A).
In the presence of F39L and I65T increasing initial blood
phenylalanine concentrations were associated with a decrease
in BH4 responsiveness. While patients with F39L still displayed
positive response at 1000 mM phenylalanine (.30% decrease in
blood phenylalanine), those carrying I65T did not show a drug
response when initial blood phenylalanine concentrations
were .800 mM. The mutation Y414C led to inconsistent
response to BH4 with maximum responsiveness at initial
blood phenylalanine concentrations up to 750 mMphenylalanine
and at 1000 mM phenylalanine. In general, patients bearing the
mutation Y414C showed a high degree in BH4 responsiveness
with the lowest response remaining within the range of 30%
decrease in blood phenylalanine.
Patients bearing the mutation R261Q showed strong incon-
sistencies in BH4 responsiveness with some patients display-
ing high levels of responsiveness (.60% decrease of blood
phenylalanine) and others no response at all (Fig. 4B). To
investigate the basis of these inconsistencies, we analyzed
the impact of both the genotype on BH4 response and of
phenylalanine concentrations on different genotypes compris-
ing the R261Q mutation. The decrease in blood phenylalanine
concentrations was significantly stronger in individuals carry-
ing the R261Q mutation in the homozygous state (median,
37.5%) than those carrying it in the functional hemizygous
state (median, 6.5%). However, among homozygous patients,
some were responders and some were not, whereas all func-
tionally hemizygous patients had to be classified as non-
responders. Interestingly, the level of initial blood phenyl-
alanine did not allow differentiating either homozygous
responders from homozygous non-responders or homozygotes
from functional hemizygotes.
In addition to the influence of initial blood phenylalanine
concentrations on BH4 response, we analyzed the impact of
the genotype on BH4 dose response to investigate the
optimal PAH working range in vivo. Literature data providing
information on BH4 dosage revealed clear differences for
patients homozygous for R261Q, patients homozygous for
Y414C and those compound heterozygous for these two
mutations (Fig. 4C). In the presence of the mutation R261Q,
the percent decrease in blood phenylalanine levels remained
nearly unchanged for the range of BH4 dosages between 10
and 30 mg/kg body weight. In contrast, patients bearing the
mutation Y414C showed a gain in BH4 response with increas-
ing BH4 doses (5–20 mg/kg body weight). Interestingly,
patients compound heterozygous for R261Q and Y414C
showed an intermediate response with respect to the BH4
dosage administered (10–20 mg/kg body weight) when com-
pared with patients homozygous for these mutations.
As a conclusion, in vivo PAH activity is a function of the
phenylalanine substrate and the BH4 cofactor as well as the
patient’s genotype. Hence, enzyme function in the individual
patient at a given time point is the resultant of the metabolic
state and the dosage of cofactor treatment both in turn deter-
mined by the underlying mutations.
DISCUSSION
Regulation of PAH activity is essentially governed by the
abundance of the phenylalanine substrate and the BH4
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cofactor. The supply of substrate, e.g. upon food intake,
induces enzyme activation and subsequently full catalytic
activity. In contrast, at low blood phenylalanine levels, e.g.
under fasting conditions, BH4-induced PAH inhibition pre-
vents from undue elimination of the essential amino acid
phenylalanine. Thus, it is the ratio of phenylalanine to BH4
that determines activation and inhibition of the enzyme.
However, the concentration of BH4 in the liver cell is held
rather constant, whereas phenylalanine levels undergo
substantial fluctuations in function of the metabolic state
and—in the presence of PAH deficiency—of the underlying
genotype. While treating patients with BH4 we intervene in
this system without disposing of profound knowledge concern-
ing the effect of shifts of the substrate-to-cofactor ratio. In the
work presented here, we first wanted to apply the newly devel-
oped real-time fluorescence-based PAH enzyme activity assay
to identify the optimal working range of the enzyme with
respect to these substances. Secondly, we aimed to analyze
Figure 4. Evaluation of BH4 responsiveness in PAH-deficient patients. (A) The impact of the genotype and of initial blood phenylalanine concentrations on BH4
response. The graphs show the percent decrease in blood phenylalanine levels 24 h after a single dose of BH4 (20 mg/kg bw) in patients homozygous or func-
tional hemizygous for the mutations F39L (n ¼ 3), I65T (n ¼ 5) or Y414C (n ¼ 10) as a function of different blood phenylalanine values at the beginning of the
test. The horizontal dashed line indicates 30% decrease in blood phenylalanine concentrations, the arbitrary criterion of BH4 responsiveness. The vertical dashed
line shows the initial blood phenylalanine concentration, above which BH4 leads to a blood phenylalanine decrease of ,30%. (B) BH4 responsiveness in patients
carrying the mutation R261Q (n ¼ 28). (Left) Percent decrease in blood phenylalanine 24 h after a single dose of BH4 (20 mg/kg bw) as a function of initial
blood phenylalanine values in patients homozygous or functional hemizygous for the R261Q mutation. (Middle) Percent decrease in blood phenylalanine
24 h after a single dose of BH4 (20 mg/kg bw) in patients carrying the R261Q mutation in the homozygous state (n ¼ 22) in comparison to functional hemi-
zygotes (n ¼ 6). The boxes show the interquartile ranges (25th to 75th percentiles), the horizontal black bars represent the median, the bars indicate the
range. Significance is indicated (∗∗P, 0.01, unpaired Student’s t-test). (Right) Percent decrease in blood phenylalanine concentrations in function of initial
blood phenylalanine values in homozygous responders (n ¼ 13) and non-responders (n ¼ 9) as well as functional hemizygous patients (n ¼ 6) displaying the
mutation R261Q. (C) The impact of the genotype on BH4 dose response. Percent decrease in blood phenylalanine 24 h after a single application of BH4 in
different dosages in patients homozygous for R261Q (n ¼ 24) (left), homozygous for Y414C (n ¼ 10) (middle) or compound heterozygous for R261Q/
Y414C (n ¼ 3) (right).
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the influence of changes in the phenylalanine-to-BH4 ratio on
PAH function of the wild-type and variant enzymes.
Analyses of wild-type PAH revealed two interesting new
findings. In addition to the well-known enzyme inhibition by
the substrate, cofactor inhibition was identified by the exten-
sion of the enzyme activity assay to much higher cofactor con-
centrations. Moreover, we learned that with increasing
phenylalanine concentrations, more BH4 is needed to maintain
the same level of PAH activity. Still, it has to be considered
that the full range of substrate and cofactor concentrations
applied in our novel assay provided new insights into theoreti-
cal aspects of PAH enzymology, but it is well beyond physio-
logical levels. However, our approach allowed for detailed
visualization and better understanding of conditions corre-
sponding to those occurring at the edges of classical pathologi-
cal situations in PKU patients and in the therapeutic context
upon cofactor treatment.
The optimal working range of the wild-type enzyme
occurred at phenylalanine concentrations of 250–500 mM.
From a physiological point of view, this appears reasonable,
since upon food intake liver phenylalanine concentrations
are expected to reach levels up to 500 mM rather than around
1000 mM, the phenylalanine concentration at which standard
PAH enzyme activity assays are performed (2,38). Our
results showed that the optimal BH4 concentration for PAH
enzyme activity is 100 mM, while standard PAH activity
assays are run at 75 mM BH4 (2,38). In any case, the physio-
logical cellular BH4 concentration in the liver is by far
lower (8.5 mM) (26), implying that the cell has always to
be considered BH4 deficient in view of the enzymatic task.
Yet, in light of the inhibitory potential of BH4 on the
enzyme, a cellular cofactor concentration significantly below
the Km value of 23 mM reduces inhibition when activity is
needed, i.e. at phenylalanine concentrations above the physio-
logical range. The trade-off between these two tasks is
balanced by a 6-fold higher affinity of the enzyme toward
the cofactor (Km, 23 mM) than toward the substrate (S0.5,
145 mM). As a consequence, PAH binds BH4 and phenyl-
alanine at a ratio of 0.5 at 100 mM blood phenylalanine (inhi-
bition) when compared with 0.09 at 561 mM blood
phenylalanine (no inhibition). These theoretical assumptions
are corroborated by previous in vivo 13C-phenylalanine oxi-
dation tests performed in a PKU mouse model (39). In the
euphenylalaninemic state, a hypothetical BH4 deficiency is
overruled by an inhibitory effect following the application of
BH4 in wild-type animals. However, in hyperphenylalanine-
mia phenotypes, the administration of BH4 leads to an
immediate increase in 13C-phenylalanine oxidation. In view
of a time to effect of ,5 min, this has to be considered inde-
pendent of a pharmacological chaperone effect and rather
points to compensation of BH4 deficiency in this metabolic
state. Comparable studies in humans addressing phenylalanine
concentrations, BH4 concentrations, the effect of BH4 in
healthy individuals, time to onset of action and effect duration
would be of interest, but have not yet been performed.
Next, we investigated the effect of selected missense
mutations in the PAH gene on the optimal working range of
the enzyme. In general, activity landscapes of the wild-type
and variant PAH proteins displayed comparable patterns
with rather high residual enzyme activity and a limited area
of maximum activity. More detailed analyses, however,
revealed various alterations with respect to the extension and
position of the optimal working range in the coordinates of
substrate and cofactor concentrations. Most variant proteins
were in need of more BH4 to achieve peak activity (F39L,
I65T, R261Q, P275L, Y417H, Y414C). For two variants
(R261Q and P275L), maximum activity was determined at
markedly higher phenylalanine concentrations (842 and
1293 mM). In contrast, three variants (P314S, Y414C and
Y417H) presented a narrowed optimal working range that
was shifted to lower phenylalanine concentrations when com-
pared with the wild-type.
Two of these mutations, R261Q and Y414C, are frequent,
but inconsistently associated with BH4 responsiveness
(17,34–37). The analysis of activity landscapes provided
first evidence for an impact of the metabolic state on variant
PAH function. R261Q displayed marked reduction in
enzyme activity at phenylalanine concentrations in the thera-
peutic range below 240 mM giving rise to the hypothesis that
patients bearing this mutation in the homozygous or functional
hemizygous state would not benefit from a restrictive dietary
regime. On the other hand, the mutation Y414C that induces
a shift of activity to lower phenylalanine concentrations
would require a rather strict metabolic adjustment with low
blood phenylalanine values to achieve optimized PAH
activity. Thus, observations from the analysis of activity land-
scapes could be of importance for a deeper understanding of
inconsistent results from BH4 loading tests or some disap-
pointing experiences upon BH4 treatment of our patients. To
perform a further step in this direction, we carried out cell
culture experiments and analyzed data from BH4 loading
tests performed in PKU patients.
Data extracted from activity landscapes were reproduced in
the setting of stably transfected cells. Having gained insights
into the mutual impact of varying substrate and cofactor con-
centrations on PAH activity, we were then interested in
answering the question of how changes in the metabolic
state would affect the effective PAH concentration, that is,
the intracellular amount of functional PAH enzyme available
for phenylalanine conversion. Since BH4 has been classified
as a pharmacological chaperone, i.e. a stabilizing compound
that helps to overcome PAH degradation in the cell, it is
expected to raise the amount of PAH in cell culture. In
addition, we had previously shown that the effective PAH con-
centration is influenced by changes in the
phenylalanine-to-BH4 ratio in the mouse (12). To address
these issues in cell culture, we mimicked physiological
(euphenylalaninemic) and pathologic (hyperphenylalanine-
mic) conditions representing classical PKU. The supplemen-
tation of BH4 induced diverse results in the presence of
R261Q and Y414C, respectively. BH4 was beneficial for cat-
alytic PAH function of the R261Q variant particularly at low
phenylalanine levels, whereas a significant increase in PAH
enzyme activity reflecting an increase in the effective PAH
amount was observed for Y414C under PKU conditions. Inter-
estingly, the therapeutic range for BH4 was narrow for Y414C,
a finding confirming the observations from the activity land-
scapes.
As a next step, we aimed to verify the clinical relevance
of our findings and analyzed the effect of different substrate
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and cofactor concentrations on the outcome of single dose
BH4-loading tests in individuals carrying different PAH gen-
otypes. In clinical routine, the initial phenylalanine concen-
tration at the beginning of the BH4-loading test is not
expected to significantly affect the outcome of the test. In
general, only a minimum phenylalanine concentration of
400 mM is considered to be required for reliable test
results. Surprisingly, data from BH4 loading tests available
in the BIOPKU database and in the literature (19,33–
37,40) does not confirm this view. We learned that patients
carrying one of the mutations F39L, I65T or Y414C in
either a homozygous or a functional hemizygous state
show substantially different responses to the BH4-loading
test in function of the phenylalanine concentration at the
beginning of the test. For example, in presence of the
mutation I65T, the response may vary from 60% at
500 mM phenylalanine to 0% at 1500 mM blood phenyl-
alanine. This is a new finding that may undermine our
trust in current BH4-loading test protocols. Our results
may, for instance, allow for the hypothesis that patients car-
rying the I65T mutation are at risk to show false negative
test results at phenylalanine concentrations .750 mM. In
the case of the R261Q mutation, phenylalanine concen-
trations did not significantly influence test results
(Fig. 4B). However, the kind of genotype significantly
affected BH4 responsiveness with carriers of the R261Q
mutation in the homozygous state showing a higher
response (37.5% decrease in phenylalanine after BH4
loading) than individuals with the mutation in the functional
hemizygous state (6.5% decrease). Further analysis revealed
that none of the patients carrying the R261Q mutation in
combination with a null mutation met the criterion of BH4
responsiveness of 30% decrease of phenylalanine concen-
trations, whereas 12 out of 21 patients with a homozygous
genotype did and 9 out of 21 patients did not. Similar
observations were recently reported in 27 Turkish PKU
patients with a homozygous R261Q genotype and variable
clinical phenotypes (11% mild hyperphenylalaninemia,
67% mild PKU, 22% classic PKU), from which only
39.1% were BH4 responsive (22). Taken together, our
results show that the outcome of a BH4-loading test may
much more vary in function of individual test circumstances
than previously assumed. Unfortunately, it has to be
expected that this is true for a number of mutations and
in view of the lifelong consequences for our patients
arising from the initial classification of being a responder
or not it has to be emphasized that with the knowledge
available today results from single-loading tests are not suf-
ficient to determine BH4 responsiveness in patients with
PAH deficiency.
Last, we analyzed the effect of BH4 dosage on the results of
single BH4-loading tests. Since 10 years, a dosage of 20 mg/
kg body weight is internationally recommended (11,28,29,41).
However, in some centers and countries, this recommendation
may not be followed. In homozygous R261Q patients, the
dosage of BH4 (10, 20 and 30 mg/kg body weight) did not
seem to influence test results (26, 27 and 25% decrease,
respectively). In presence of the Y414C mutation, increasing
BH4 dosages increased BH4 responsiveness in terms of
percent decrease of blood phenylalanine after BH4 application.
Interestingly, compound heterozygous patients carrying both
the R261Q and the Y414C mutation also showed a dose
dependency of response, but to a lower extent than homozy-
gous Y414C patients.
In summary, we developed a rapid PAH enzyme activity
assay allowing for a much higher throughput than previous
assays and for detailed analysis of a broad range of substrate
and cofactor concentrations on PAH enzyme kinetics. This
enabled new insights into optimal PAH working range at phys-
iological, pathological and therapeutic conditions. As to
enzyme kinetics, two main conclusions can be drawn from
our experimental work: phenylalanine concentrations for
optimal working range of PAH are lower, whereas BH4 con-
centrations for optimal PAH activity are higher than pre-
viously assumed. The validity of our observations was
substantiated and expanded by the fact that we were able to
translate data from the prokaryotic system into the eukaryotic
cell culture system and into patient data. Of relevance for the
clinical context, we revealed a significant impact of the geno-
type, substrate concentrations and BH4 dosage on the assess-
ment of BH4 responsiveness.
Since the discovery of the pharmacological effect of BH4 in
patients with PAH deficiency (5), the scientific community
discusses possible mechanisms of BH4 responsiveness in
PKU. The initial concept was kinetic action, in particular the
hypothesis that PAH gene mutations lead to decreased affinity
of the variant protein to the cofactor, that is overcome by the
administration of pharmacological doses of BH4. Kinetic
studies using the recombinant PAH protein revealed that this
is true only in rare instances (2,32,42). Subsequent work
moved the concept away from kinetic effects toward the
view of BH4 acting as a molecular chaperone by increasing
the stability of partially misfolded PAH proteins and by this
the effective intracellular concentration of functional PAH
enzyme (3,4,12). A deeper view into PAH enzyme kinetics
using a technology that allows for the analysis of a broad
range of substrate and cofactor concentrations on PAH activity
now showed that besides the indubitable chaperone effect,
kinetic aspects also have to be taken into account. Thus, we
may now put forward the view of both concepts being of rel-
evance for the diagnosis and the treatment of patients with
PAH deficiency. The diagnostic loading test with BH4 or long-
term BH4 treatment has to be seen in the light of the fact that
short-term supply of BH4 can compensate for latent BH4
deficiency as to optimal catalytic function (kinetic effect),
whereas long-term treatment with pharmacological doses of
BH4 increases the stability of PAH and by this the amount
of metabolically active enzyme (chaperone effect). In
addition, individual mutations may shift the impact of one or
the other therapeutic effect.
For daily clinical routine, this underscores the need for even
more standardized and at the same time individualized test
procedures including detailed documentation of phenylalanine
concentrations before the BH4 load and the awareness that the
metabolic status of the patient will influence the outcome of
the test. In non-responders with suggestive genotypes, re-
petition of the loading test at different initial phenylalanine
concentrations may help rule out false negative results. More-
over, we suggest to combine short-term BH4 loading tests
(assessment of kinetic effects) and long-term BH4 treatment
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tests (assessment of chaperone effects) with in vivo 13C-
phenylalanine oxidation tests (assessment of the effect of
BH4 on in vivo PAH enzyme activity) (11,43). The test is non-
invasive, innocuous, easy to perform and may add important
information about an individual’s response to the drug at a
functional level.
In conclusion, our work pinpoints the importance of geno-
typing PKU patients even in clinical routine and underscores
the need for more personalized testing procedures addressing
individual patient characteristics, the metabolic state and the
dosage of the test compound to safely identify BH4 respon-
siveness in PAH-deficient patients.
MATERIALS AND METHODS
Patients and mutations
Mutations previously identified in BH4 responsive patients
(4,11) were analyzed in terms of the effect of various substrate
(L-phenylalanine) and cofactor (BH4) concentrations on PAH
enzyme activity. The mutations mapped to the regulatory
domain (F39L, I65T), the catalytic domain (R261Q, P275L,
P314S, V388M) or to the dimerization motif of the oligomer-
ization domain (Y414C, Y417H). Forty-six patients homozy-
gous and functional hemizygous for the mutations F39L
(n ¼ 3), I65T (n ¼ 5), R261Q (n ¼ 28) and Y414C (n ¼ 10)
were identified performing a comprehensive literature survey
and by extracting data from the BIOPKU database (www.
biopku.org). Patients were included in the analysis, when
data on a BH4-loading test using 20 mg/kg body weight and
blood phenylalanine concentrations over a period of at least
24 h were available. In addition, the effect of different BH4
dosages, ranging from 5 to 30 mg/kg body weight, on the
course of blood phenylalanine concentrations was analyzed
(16,19,34,35,37).
Expression and purification of recombinant PAH proteins
The cDNA of human PAH (EST clone obtained from ima-
Genes, formerly RZPD, Germany) was cloned into the prokar-
yotic expression vector pMAL-c2E (New England Biolabs)
encoding an N-terminal maltose-binding protein (MBP) tag.
PAH mutants were constructed by site-directed mutagenesis
as previously described (2). Expression plasmids containing
the wild-type PAH and variants were transformed to Escheri-
chia coli DH5a. Expressed proteins were purified by affinity
chromatography (MBPTrap, GE Healthcare) followed by
size-exclusion chromatography using a HiLoad 26/60 Super-
dex 200 column (GE Healthcare) on an A¨KTAxpress system
(2). Obtained tetramers of the fusion proteins were collected
and protein concentrations were determined spectrophotome-
trically using 1280 (1mg/ml) ¼ 1.63.
PAH activity assay
Enzyme activity of the recombinantly expressed PAH. The
multi-well PAH activity assay and data evaluation were per-
formed as previously described (27) with modifications.
L-phenylalanine and 22.35 mM Na HEPES, pH 7.3, were
added to all wells of a 96-well plate with different volumes.
This resulted in 12 columns of varying L-phenylalanine con-
centrations (0–4000 mM). A reaction buffer containing 1 mg/
ml catalase (Sigma-Aldrich), 10 mM ferrous ammonium
sulfate (Sigma-Aldrich) and the tetrameric MBP–PAH
fusion protein (0.01 mg/ml) was prepared and injected in all
96 wells. After pre-incubation with L-phenylalanine for 5–
20 min, the reaction was initiated by the addition of variable
concentrations of BH4 (6R-L-erythro-5,6,7,8-tetrahydrobiop-
terin, Cayman Chemical) (0–500 mM) stabilized in 100 mM
dithiothreitol (DTT; Fluka Chemie). PAH activity was deter-
mined at 258C and 90 s measurement time per well. Using
sets of 16 wells and 10 measurement cycles per set, total
measurement time for all 96 wells was 22 min. Substrate pro-
duction was measured by the detection of the increase in
L-tyrosine fluorescence intensity, at an excitation wavelength
of 274 nm and an emission wavelength of 304 nm, using a flu-
orescence photometer (FLUOstar OPTIMA, BMG Labtech)
and assayed as triplicates. Measured fluorescence intensity
signals were corrected by the inner filter effect of BH4 for
every BH4 concentration added. Enzyme activity measure-
ments were quantified by the measurement of L-tyrosine stan-
dards (0–200 mM) before each experiment, and fluorescence
intensity was converted to enzyme activity units (nmol
L-tyrosine/min × mg protein). Data were analyzed by non-
linear regression analysis using the Michaelis–Menten or the
Hill kinetic model after comparison of model-fitting using
the F-test (GraphPad Prism 4.0c) (27). All concentrations
mentioned refer to the final concentration in a 202 ml reaction
mixture.
Standard PAH activity assay of eukaryotic expressed PAH.
PAH enzyme activity was determined as previously described
(2,39) with modifications. Twenty microliters of total lysates
obtained from cell culture were pre-incubated with 1000 mM
L-phenylalanine and 1 mg/ml catalase (Sigma-Aldrich) for
5 min (258C) in 15 mM Na HEPES pH 7.3, followed by
1 min incubation with 10 mM ferrous ammonium sulfate
(Sigma-Aldrich). The reaction was initiated by the addition
of 75 mM BH4 stabilized in 2 mM DTT, carried out for
60 min at 258C and stopped by acetic acid followed by
10 min incubation at 958C. All concentrations mentioned
refer to the final concentration in a 100 ml reaction mixture.
The amount of L-tyrosine production was measured and quan-
tified by HPLC, assayed as duplicates. Three independent
experiments were performed.
PAH activity landscapes
The data set of multi-well enzyme activity assayed in a 12 × 8
matrix corresponding to 12 different L-phenylalanine concen-
trations ranging from 0 to 4000 mM (columns) at 8 BH4 con-
centrations ranging from 0 to 500 mM (rows) was loaded into
non-linear regression analysis software (GraphPad Prism
4.0c). A non-linear regression analysis was performed for
each column of the data matrix in order to extend the sparse
data set for BH4 concentrations from 8 measured to 400
newly calculated values following a substrate inhibition
curve. This resulted in a 12 × 400 matrix of activity values.
For further calculation of the data and for the creation of land-
scapes, this data matrix was exported to the free software
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package R (www.r-project.org). In order to draw a smooth
surface of the landscape, we used the function interp.loess
from additional R package tgp (http://cran.r-project.org/
web/packages/tgp/index.html), which interpolates between
two data points by using local polynomial regression fitting
to find a function between them. This resulted in an increase
in data from an originally measured 12 × 8 (96-well format)
over a 12 × 400 to a 400 × 400 data set. This grid was
then depicted as a smooth landscape plot using the function
image.plot from package fields (http://cran.r-project.org/
web/packages/fields/index.html). To facilitate calculation of
landscapes, a script was written accepting comma-separated
files and automatically coloring landscapes depending on the
measured and interpolated fluorescence intensities.
Stable expression of PAH in HEK293
Stably transfected cells were generated using the Flp-In
system (Invitrogen) according to the manufacturer’s protocol.
The Flp-In-293 cell line was maintained in basic DMEM
(PAA Laboratories) supplemented with L-glutamine, high
glucose (4.5 g/l), 10% fetal bovine serum (GIBCO), 1% anti-
biotics (Antibiotic-Antimycotic; PAA) and 100 mg/ml Zeocin
(Invitrogen). Cells were stably transfected with pEF5/FRT/
V5-DEST cDNA constructs coding for the wild-type, R261Q
or Y414C PAH, respectively. Positive clones were selected
and maintained in medium containing 150 mg/ml hygromycin
B (Invitrogen).
For all further experiments, cells were cultured for 72 h
under three different conditions: (i) basic RPMI 1640
medium (91 mM phenylalanine, PAA Laboratories) sup-
plemented with stable glutamine, 10% fetal bovine serum
(GIBCO), 1% antibiotics (Antibiotic-Antimycotic; PAA) and
150 mg/ml of hygromycin B, (ii) basic medium (as described
above) with 500 mM phenylalanine, and (iii) basic medium
with 1200 mM phenylalanine. Additionally, culture conditions
were modified by adding 40 or 75 mM BH4, respectively.
Culture medium was changed every 24 h. Cells were harvested
and lysed by three freeze-thaw cycles in a Tris–KCl lysis
buffer (0.03 M Tris, 0.2 M KCl, pH 7.2) containing protease
inhibitors (Roche), followed by 20 min centrifugation at
3000 rcf, 48C. Recovered supernatants were subsequently
used for activity assays.
Statistics
Group mean values were compared by Student’s unpaired
two-tailed t-test. Eukaryotic PAH activities following BH4
treatment were analyzed by one-way ANOVA and Dunnett’s
post-test. Statistical analyses were performed using GraphPad
Prism 4.0c (GraphPad Software).
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